

# BIOMARKERS AND TOXICITY MECHANISMS 14 – BIOMARKERS Summary and final notes

Luděk Bláha, PřF MU, RECETOX www.recetox.cz

Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.









# Topics covered in the final presentation

- Biomarkers at different levels
  - Omics
  - and beyond


- Biomarkers in human medicine and drug development
  - Strategy and steps in development
  - Application examples



# Biomarkers at various levels "omics"



### Biomarkers at different biological levels – "omics" approach



### Biomarkers at different biological levels

# "Omics" techniques


- Systems biology research
- Screenings of responses (differences) at all levels of biological organization

### GENOMICS

- Relatively stable
  - not responding to environmental changes (e.g. Toxicants)
- Can be used as "biomarkers of susceptibility" (SNPs and personalized medicine)
- OTHER "OMICS" (Transcripts, Proteins, Metabolites...)
  - Resposive to environmental stress (including toxicants, therapy etc.)




# Biomarkers at different biological levels



Hypothesis driven research (focus on pathways)


Data driven research (omics & profiling)



Alternative Approach (Proteome Profiling) SELDI-TOF MS CE-MS Microarrays Microfluidics Biomarker Discovery Clinical Diagnostics


- and/or Pathogenic Mechanisms
   Defining New Therapeutic Targets
- Biomarker Discovery

### Biomarkers at even higher levels – example: toxic metals



Early warning to individual health

Early warning from population to ecosystem health






# Developments and applications of biomarkers



### 3 key steps towards the biomarker establishment

An example of protein-based biomarkers



### 3 key steps towards the biomarker establishment

# Biomarker development

- High numbers of endpoints (e.g. proteins)
- Low numbers of samples compared (e.g. 10 controls vs 10 "treatments")

### Biomarker validation


- Decreasing number of markers
- Increasing numbers of specimens (biological samples)


# Biomarker qualification and approval

- Individual markers
- Analytical methods validated and well established




### More detailed view: 5 steps leading to biomarker use in practice





### EXAMPLE process of biomarker establishment – lung cancer diagnosis



#### Protein preparation and separation

- Protein Enrichment: Glycoproteome
   Phosphoproteome
- · SDS-PAGE: 1-DE, 2-DE
- In-gel trypsin digestion

#### Biomarker discovery

- · LC-ESI-MS/MS
- · MALDI-TOF/MS

# WALDI-VS


#### Biomarker candidates verification & validation

- MRM (Multiple Reaction Monitoring)
- Western Blot
- ELISA

# Which of the many changes are "significant"?

→ Use quantitative metrics (see Following slide)

# What is (what is not) a candidate biomarker: example flowchart



### Biomarkers have MANY APPLICATIONS ... such as:

### Biomarkers in research

- Search of "potential" therapies/drugs
  - Changes in biochemical responses provide information on efficiency and mechanism of action
- Identification of "early markers" of chronic diseases
  - Early diagnosis (e.g. identification of developing cancer, coronary disease...)

### Biomarkers in medicine

- Identification of status of an individual
  - Healthy vs Disease
- Assessment of therapy/treatment
  - Efficiency Did treatment improved situation? (improvements in biomarker responses)
  - Adverse or side effects of therapy


### Biomarkers in toxicology

- Identification of status
  - Intoxicated (exposed) vs Controls
  - Forensic toxicology (e.g. consumption of drugs of abuse, alcohol etc)
- Early warnings of future health consequences
  - Biochemical changes are detectable before the actual health problems



### Biomarker validation EXAMPLE

Kim-1 protein levels and kidney clinical signs (histopathology grades 0-3)




**FIGURE 22.4** Boxplots of Kim-I values by kidney histopathology injury grade. A plot of the individual values sorted by Kim-I value is superimposed over each, giving a finer scaled picture of the distribution of the data. The figure indicates that median Kim-I values generally increase with an increased histopathology score. Also, some samples in the group of animals treated with a nephrotoxicant but with histopathology scores of zero have elevated Kim-I levels. (See color insert for a full color version of this figure.)




### OMICS biomarkers in discovery and validation (1/2)





### OMICS biomarkers in discovery and validation (2/2)





# Summary and overview

Class on toxicity mechanisms (MoA) and biomarkers



### Class summary and take home message

- \* Molecular effects of toxicants = MoAs (1)
- \* Propagate to higher levels (2),
- \* ... where they induce measurable "responses" biomarkers (3)

1

#### MoAs

- \* Molecular interactions
- \* Key targets ...:
  - DNA, RNAs
  - proteins (and their functions)
  - membranes
- \* Complex mechanisms
  - Oxidative stress
  - Signalling and hormones
  - Detoxification



3

### **Biomarkers**

- types
- examples
- methods

Biological organization



### Summary on toxicity mechanisms (MoA) and biomarkers

### For excellent performance and successful exam student should:

- have an overview of different types of MoAs (see also point 2 below) and be able to link MoAs to higher level effects (toxicity)
  - Example: inhibition of AcCholE enzymes (mechanism) → propagates as neurotoxicity (effect)
- 2. know some **details for selected example MoAs** for different toxicant targets = based on your own interest select one example from each of the following categories, learn details, be able to discuss (i.e. know details for 7 example modes of toxic action)
  - 1. nucleic acids
  - 2. proteins
  - 3. membranes (lipids)
  - 4. cellular
  - 5. Complex 1 detoxification/metabolization
  - 6. Complex 2 intra- and inter-cellular signalling, hormones
  - 7. Complex 3 oxidative stress
- 3. have understanding of biomarker issues
  - What is a biomarker and what properties it should have (or not to have)?
  - Why we search for them = how can they be used?
  - What different types and groups of biomarkers can be recognized?
  - What are suitable matrices for sampling and further analyses?
  - What approaches are applied in biomarker discovery ("hypothesis" vs omics)?
- 4. and know example biomarkers same approach as for point 2 above = based on your own interest select one example biomarker for each of seven categories and know some details)

